3-(methylaminomethyl)-5-hexen-1-ol | 1100595-14-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-(methylaminomethyl)-5-hexen-1-ol
• 英文别名: 3-methylaminomethyl-5-hexenol；3-(Methylaminomethyl)hex-5-en-1-ol
• CAS: 1100595-14-9
• 化学式: C₈H₁₇NO
• mdl: MFCD19220808
• 分子量: 143.229
• InChiKey: HUXJFIUTDOIJMK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(methylaminomethyl)-5-hexen-1-ol 、 (-)-(3R,4S,5S,6R,8R,9R)-9-acetoxy-5-[2-O-acetyl-4-O-(2,6-dideoxy-3-C-methyl-4-O-propionyl-α-L-ribo-hexopyranosyl)-3,6-dideoxy-3-dimethylamino-β-D-glucopyranosyl]-6-(2,2-dimethoxyethyl)-4-methoxy-8-methyl-10-oxo-3-propionyloxydecanoic acid 在 溶剂黄146 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成
  参考文献：
  名称：

  衍生自16元大环内酯的新型氮杂内酯。第二部分：直链9-甲酰基羧酸的分离及其与氨基醇或叠氮基胺的顺序大环化。

  摘要：

  报道了从16元大环内酯类化合物开始的新型14至16元11-氮杂叠氮化物的设计和合成。通过先前报道的移动二醛分离线性9-甲酰基羧酸。用氨基醇对甲酰基羧酸进行顺序大环化，然后脱保护，得到相应的14至16元氮杂内酯。另一方面，用叠氮基胺对甲酰基羧酸进行还原胺化，然后用由叠氮化物生成的胺形成大内酰胺，得到14至16元的氮杂内酰胺。在这些衍生物中，15元氮杂内酰胺和16元氮杂内酯类药物表现出特征性的体外抗菌活性。尽管优化包括脱麦芽糖基类似物的15元氮杂内酰胺不能提供非常有前途的分子，

  DOI：

  10.1016/j.bmc.2008.09.054

文献信息

• NOVEL AZALIDE AND AZALACTAM DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE SAME
  申请人：Meiji Seika Kaisha, Ltd.

  公开号：EP1661904A1

  公开（公告）日：2006-05-31

  A compound represented by the following general formula (1) or a pharmaceutically acceptable salt thereof, which is useful for a prophylactic and/or therapeutic treatment of a microbial infectious disease. [R1 is hydrogen atom, or a linear C1-6 alkylcarbonyl group; R2 is hydrogen atom, or a C1-6 alkylcarbonyl group; R3 is hydrogen atom, a C1-6 alkyl group, a C1-6 alkylcarbonyl group, a C1-6 alkenyl group, a C2-6 alkenylcarbonyl group, a C2-6 alkynyl group, or an Ar-B- group (Ar represents an aryl group, or a heterocyclic group, and B is a C1-6 alkyl group, a C1-6 alkylcarbonyl group, a C2-6 alkenyl group, a C2-6 alkenylcarbonyl group, or a C2-6 alkynyl group); R5, R6, R7, and R8 represent hydrogen atom, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, or an Ar-B'- group (B' is a C1-6 alkyl group, a C2-6 alkenyl group, or a C2-6 alkynyl group); X is oxygen atom, or an -NR4- group (R4 is hydrogen atom, a C1-6 alkyl group, or a C1-6 alkyl group which may be substituted with an Ar group); and R4' is hydrogen atom, or a group represented by the aforementioned formula (a) (R3" and R4" represent hydrogen atom, or a linear or branched C1-6 alkylcarbonyl group)]

  由以下一般式（1）表示的化合物或其药学上可接受的盐，可用于预防和/或治疗微生物感染性疾病。[R1为氢原子，或线性C1-6烷基羰基基团；R2为氢原子，或C1-6烷基羰基基团；R3为氢原子，C1-6烷基基团，C1-6烷基羰基基团，C1-6烯基基团，C2-6烯基羰基基团，C2-6炔基基团，或Ar-B-基团（Ar表示芳基团，或杂环基团，B为C1-6烷基基团，C1-6烷基羰基基团，C2-6烯基基团，C2-6烯基羰基基团，或C2-6炔基基团）；R5、R6、R7和R8表示氢原子，C1-6烷基基团，C2-6烯基基团，C2-6炔基基团，或Ar-B'-基团（B'为C1-6烷基基团，C2-6烯基基团，或C2-6炔基基团）；X为氧原子，或一个-NR4-基团（R4为氢原子，C1-6烷基基团，或C1-6烷基基团，可能被芳基取代）；R4'为氢原子，或由上述式（a）表示的基团（R3"和R4"表示氢原子，或线性或支链状C1-6烷基羰基基团）]
• Nozel azalide and azalactam derivatives and method for producing the same
  申请人：Miura Tomoaki

  公开号：US20070042974A1

  公开（公告）日：2007-02-22

  A compound represented by the following general formula (1) or a pharmaceutically acceptable salt thereof, which is useful for a prophylactic and/or therapeutic treatment of a microbial infectious disease. [R 1 is hydrogen atom, or a linear C1-6 alkylcarbonyl group; R 2 is hydrogen atom, or a C1-6 alkylcarbonyl group; R 3 is hydrogen atom, a C1-6 alkyl group, a C1-6 alkylcarbonyl group, a C1-6 alkenyl group, a C2-6 alkenylcarbonyl group, a C2-6 alkynyl group, or an Ar—B— group (Ar represents an aryl group, or a heterocyclic group, and B is a C1-6 alkyl group, a C1-6 alkylcarbonyl group, a C2-6 alkenyl group, a C2-6 alkenylcarbonyl group, or a C2-6 alkynyl group); R 5 , R 6 , R 7 , and R 8 represent hydrogen atom, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, or an Ar—B′— group (B′ is a C1-6 alkyl group, a C2-6 alkenyl group, or a C2-6 alkynyl group); X is oxygen atom, or an —NR 4 — group (R 4 is hydrogen atom, a C1-6 alkyl group, or a C1-6 alkyl group which may be substituted with an Ar group); and R 4′ is hydrogen atom, or a group represented by the aforementioned formula (a) (R 3″ and R 4″ represent hydrogen atom, or a linear or branched C1-6 alkylcarbonyl group)]

  下列通式（1）所代表的化合物或其药学上可接受的盐，可用于预防和/或治疗微生物感染性疾病。[其中R1为氢原子或线性C1-6烷基羰基基团；R2为氢原子或C1-6烷基羰基基团；R3为氢原子、C1-6烷基、C1-6烷基羰基基团、C1-6烯基、C2-6烯基羰基基团、C2-6炔基或Ar-B-基团（Ar代表芳基或杂环基，B为C1-6烷基、C1-6烷基羰基基团、C2-6烯基、C2-6烯基羰基基团或C2-6炔基）；R5、R6、R7和R8代表氢原子、C1-6烷基、C2-6烯基、C2-6炔基或Ar-B′-基团（B′为C1-6烷基、C2-6烯基或C2-6炔基）；X为氧原子或-NR4-基团（R4为氢原子、C1-6烷基或可被芳基取代的C1-6烷基）；R4′为氢原子或上述通式（a）所代表的基团（R3″和R4″代表氢原子或线性或支链状C1-6烷基羰基基团）]
• US7365174B2
  申请人：——

  公开号：US7365174B2

  公开（公告）日：2008-04-29
• Novel azalides derived from 16-membered macrolides. Part II: Isolation of the linear 9-formylcarboxylic acid and its sequential macrocyclization with an amino alcohol or an azidoamine
  作者：Tomoaki Miura、Kenichi Kanemoto、Satomi Natsume、Kunio Atsumi、Hideki Fushimi、Takuji Yoshida、Keiichi Ajito

  DOI：10.1016/j.bmc.2008.09.054

  日期：2008.12

  followed by macrolactam formation with an amine generated from the azide gave 14- to 16-membered azalactams. Among these derivatives, 15-membered azalactams and 16-membered azalides exhibited characteristic in vitro antibacterial activities. Although optimization of 15-membered azalactams including demycarosyl analogues did not provide remarkably promising molecules, SAR studies of 16-membered azalides disclosed

  报道了从16元大环内酯类化合物开始的新型14至16元11-氮杂叠氮化物的设计和合成。通过先前报道的移动二醛分离线性9-甲酰基羧酸。用氨基醇对甲酰基羧酸进行顺序大环化，然后脱保护，得到相应的14至16元氮杂内酯。另一方面，用叠氮基胺对甲酰基羧酸进行还原胺化，然后用由叠氮化物生成的胺形成大内酰胺，得到14至16元的氮杂内酰胺。在这些衍生物中，15元氮杂内酰胺和16元氮杂内酯类药物表现出特征性的体外抗菌活性。尽管优化包括脱麦芽糖基类似物的15元氮杂内酰胺不能提供非常有前途的分子，